Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
QuintilesIMS
Cerilliant
Novartis
Accenture
US Department of Justice
Deloitte
Harvard Business School
Chubb

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021410

« Back to Dashboard

NDA 021410 describes AVANDAMET, which is a drug marketed by Sb Pharmco and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AVANDAMET profile page.

The generic ingredient in AVANDAMET is metformin hydrochloride; rosiglitazone maleate. There are forty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the metformin hydrochloride; rosiglitazone maleate profile page.
Summary for 021410
Tradename:AVANDAMET
Applicant:Sb Pharmco
Ingredient:metformin hydrochloride; rosiglitazone maleate
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 021410
Suppliers and Packaging for NDA: 021410
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410 NDA Physicians Total Care, Inc. 54868-4965 54868-4965-0 60 TABLET, FILM COATED in 1 BOTTLE (54868-4965-0)
AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410 NDA Physicians Total Care, Inc. 54868-4965 54868-4965-1 20 TABLET, FILM COATED in 1 BOTTLE (54868-4965-1)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength500MG;EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Oct 10, 2002TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 11, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:➤ SubscribePatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:➤ SubscribePatent Expiration:Oct 7, 2022Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021410

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-005 Aug 25, 2003 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-001 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-004 Aug 25, 2003 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-001 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-002 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-003 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-002 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-001 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-002 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Sb Pharmco AVANDAMET metformin hydrochloride; rosiglitazone maleate TABLET;ORAL 021410-003 Oct 10, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Novartis
Cerilliant
Fish and Richardson
Medtronic
UBS
Daiichi Sankyo
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot